258 related articles for article (PubMed ID: 16038686)
1. Vaccine pharmacotherapy for the treatment of cocaine dependence.
Martell BA; Mitchell E; Poling J; Gonsai K; Kosten TR
Biol Psychiatry; 2005 Jul; 58(2):158-64. PubMed ID: 16038686
[TBL] [Abstract][Full Text] [Related]
2. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans.
Haney M; Gunderson EW; Jiang H; Collins ED; Foltin RW
Biol Psychiatry; 2010 Jan; 67(1):59-65. PubMed ID: 19846066
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
[TBL] [Abstract][Full Text] [Related]
4. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
Bernstein DI; Edwards KM; Dekker CL; Belshe R; Talbot HK; Graham IL; Noah DL; He F; Hill H
J Infect Dis; 2008 Mar; 197(5):667-75. PubMed ID: 18260764
[TBL] [Abstract][Full Text] [Related]
5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease.
Aziz A; Aziz S; Li DS; Murphy L; Leone N; Kennedy M; Dhillon S; Van Thiel DH
J Viral Hepat; 2006 Apr; 13(4):217-21. PubMed ID: 16611186
[TBL] [Abstract][Full Text] [Related]
7. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
8. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial.
Kosten TR; Domingo CB; Shorter D; Orson F; Green C; Somoza E; Sekerka R; Levin FR; Mariani JJ; Stitzer M; Tompkins DA; Rotrosen J; Thakkar V; Smoak B; Kampman K
Drug Alcohol Depend; 2014 Jul; 140():42-7. PubMed ID: 24793366
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
[TBL] [Abstract][Full Text] [Related]
10. Human therapeutic cocaine vaccine: safety and immunogenicity.
Kosten TR; Rosen M; Bond J; Settles M; Roberts JS; Shields J; Jack L; Fox B
Vaccine; 2002 Jan; 20(7-8):1196-204. PubMed ID: 11803082
[TBL] [Abstract][Full Text] [Related]
11. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial.
Wagena EJ; de Vos A; Horwith G; van Schayck CP
Nicotine Tob Res; 2008 Jan; 10(1):213-8. PubMed ID: 18188762
[TBL] [Abstract][Full Text] [Related]
12. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
[TBL] [Abstract][Full Text] [Related]
14. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults.
Kündig TM; Senti G; Schnetzler G; Wolf C; Prinz Vavricka BM; Fulurija A; Hennecke F; Sladko K; Jennings GT; Bachmann MF
J Allergy Clin Immunol; 2006 Jun; 117(6):1470-6. PubMed ID: 16751015
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India.
Velu V; Nandakumar S; Shanmugam S; Shankar EM; Thangavel S; Kulkarni PS; Thyagarajan SP
Pediatr Infect Dis J; 2007 Nov; 26(11):1038-41. PubMed ID: 17984812
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
[TBL] [Abstract][Full Text] [Related]
19. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
[TBL] [Abstract][Full Text] [Related]
20. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
